Literature DB >> 22762501

Histone deacetylase inhibitors: structure-based modeling and isoform-selectivity prediction.

Laura Silvestri1, Flavio Ballante, Antonello Mai, Garland R Marshall, Rino Ragno.   

Abstract

An enhanced version of comparative binding energy (COMBINE) analysis, named COMBINEr, based on both ligand-based and structure-based alignments has been used to build several 3-D QSAR models for the eleven human zinc-based histone deacetylases (HDACs). When faced with an abundance of data from diverse structure-activity sources, choosing the best paradigm for an integrative analysis is difficult. A common example from studies on enzyme-inhibitors is the abundance of crystal structures characterized by diverse ligands complexed with different enzyme isoforms. A novel comprehensive tool for data mining on such inhomogeneous set of structure-activity data was developed based on the original approach of Ortiz, Gago, and Wade, and applied to predict HDAC inhibitors' isoform selectivity. The COMBINEr approach (apart from the AMBER programs) has been developed to use only software freely available to academics.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22762501     DOI: 10.1021/ci300160y

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  10 in total

1.  Discovery of a Novel HDAC2 Inhibitor by a Scaffold-Merging Hybrid Query.

Authors:  Nikita Basant; Xionghao Lin; Terry-Elinor Reid; Pradeep K Karla; Xiang S Wang
Journal:  Comb Chem High Throughput Screen       Date:  2015       Impact factor: 1.339

2.  Ligand-based and structure-based studies to develop predictive models for SARS-CoV-2 main protease inhibitors through the 3d-qsar.com portal.

Authors:  Eleonora Proia; Alessio Ragno; Lorenzo Antonini; Manuela Sabatino; Milan Mladenovič; Roberto Capobianco; Rino Ragno
Journal:  J Comput Aided Mol Des       Date:  2022-06-18       Impact factor: 4.179

3.  Structural insights into HDAC6 tubulin deacetylation and its selective inhibition.

Authors:  Yasuyuki Miyake; Jeremy J Keusch; Longlong Wang; Makoto Saito; Daniel Hess; Xiaoning Wang; Bruce J Melancon; Paul Helquist; Heinz Gut; Patrick Matthias
Journal:  Nat Chem Biol       Date:  2016-07-25       Impact factor: 15.040

4.  Limiting assumptions in molecular modeling: electrostatics.

Authors:  Garland R Marshall
Journal:  J Comput Aided Mol Des       Date:  2013-01-26       Impact factor: 3.686

5.  Disruptor of telomeric silencing 1-like (DOT1L): disclosing a new class of non-nucleoside inhibitors by means of ligand-based and structure-based approaches.

Authors:  Manuela Sabatino; Dante Rotili; Alexandros Patsilinakos; Mariantonietta Forgione; Daniela Tomaselli; Fréderic Alby; Paola B Arimondo; Antonello Mai; Rino Ragno
Journal:  J Comput Aided Mol Des       Date:  2018-01-15       Impact factor: 3.686

6.  2-Benzazolyl-4-Piperazin-1-Ylsulfonylbenzenecarbohydroxamic Acids as Novel Selective Histone Deacetylase-6 Inhibitors with Antiproliferative Activity.

Authors:  Lei Wang; Marina Kofler; Gerald Brosch; Jelena Melesina; Wolfgang Sippl; Elisabeth D Martinez; Johnny Easmon
Journal:  PLoS One       Date:  2015-12-23       Impact factor: 3.240

7.  Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation.

Authors:  Brice J Albert; Austin Niu; Rashmi Ramani; Garland R Marshall; Paul A Wender; Robert M Williams; Lee Ratner; Alexander B Barnes; George B Kyei
Journal:  Sci Rep       Date:  2017-08-07       Impact factor: 4.379

Review 8.  Computer-Aided Drug Design in Epigenetics.

Authors:  Wenchao Lu; Rukang Zhang; Hao Jiang; Huimin Zhang; Cheng Luo
Journal:  Front Chem       Date:  2018-03-12       Impact factor: 5.221

9.  Identification of isoform-selective hydroxamic acid derivatives that potently reactivate HIV from latency.

Authors:  Elleard Fw Heffern; Rashmi Ramani; Garland Marshall; George B Kyei
Journal:  J Virus Erad       Date:  2019-04-01

10.  Structural basis for the development of SARS 3CL protease inhibitors from a peptide mimic to an aza-decaline scaffold.

Authors:  Kenta Teruya; Yasunao Hattori; Yasuhiro Shimamoto; Kazuya Kobayashi; Akira Sanjoh; Atsushi Nakagawa; Eiki Yamashita; Kenichi Akaji
Journal:  Biopolymers       Date:  2016-11-04       Impact factor: 2.505

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.